tirzepatide (Mounjaro, Zepbound): the first dual GIP/GLP-1 receptor agonist

tirzepatide is a 39-amino-acid synthetic peptide developed by Eli Lilly that activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor simultaneously. it became the first-in-class dual GIP/GLP-1 receptor agonist when the FDA approved Mounjaro for type 2 diabetes in May 2022. Zepbound, the obesity formulation, followed in November 2023, and a third approval for obstructive sleep apnea came in December 2024 -- the first-ever medication approved for OSA.

what is tirzepatide and how was it engineered?

tirzepatide's 39-amino-acid sequence is primarily based on the native human GIP sequence, modified to also engage the GLP-1 receptor. four deliberate engineering choices give it its distinct pharmacology: two substitutions of the non-natural amino acid Aib (alpha-aminoisobutyric acid) for DPP-4 resistance, a C-terminal amide for protease protection, and a C20 fatty diacid conjugated at lysine-20 that binds serum albumin and extends the half-life to approximately five days, supporting once-weekly dosing.

the receptor binding profile is deliberately imbalanced. tirzepatide is a full agonist at the GIP receptor (roughly equal affinity to native GIP) and a weaker agonist at the GLP-1 receptor (approximately 5-fold lower affinity than native GLP-1). this imbalance is intentional: the GIP backbone was chosen as the primary scaffold while retaining clinically meaningful GLP-1 activity [1]. additionally, tirzepatide is a biased agonist at the GLP-1 receptor -- it preferentially activates Gs/cAMP signaling over beta-arrestin recruitment, which reduces receptor internalization compared to native GLP-1 and may sustain downstream signaling. the combination of these properties is described in the pharmacology literature as "imbalanced and biased" dual agonism, and the structural basis has been characterized at the receptor level [2].

how does it work?

both GIP and GLP-1 are incretin hormones released from the gut after eating that amplify insulin secretion from pancreatic beta-cells in a glucose-dependent way. tirzepatide activates both receptor pathways simultaneously, producing additive or synergistic effects on insulin release, glucagon suppression, appetite reduction, and fat distribution that exceed what either pathway achieves alone.

GIP receptor activation at the pancreatic level drives glucose-dependent insulin secretion through the cAMP-PKA pathway, improves beta-cell function and survival, and also directly improves white adipose tissue insulin sensitivity and lipid handling. GLP-1 receptor activation adds glucose-dependent insulin secretion and glucagon suppression, delays gastric emptying (especially early in treatment), and acts on central nervous system satiety centers in the hypothalamus and brainstem to reduce appetite and caloric intake. the biased GLP-1R agonism in tirzepatide limits receptor internalization, which may sustain insulin-stimulatory signaling beyond what an unbiased agonist would maintain at the same dose [3].

at the body-composition level, visceral fat is reduced disproportionately relative to total weight loss. a SURMOUNT-1 body-composition substudy found approximately one-third of weight lost was lean mass and two-thirds was fat mass, a ratio consistent with other anti-obesity medicines and diet-driven weight loss. GIP-mediated improvements in adipose tissue insulin sensitivity may contribute to the favorable metabolic profile beyond what weight reduction alone explains, though the exact partitioning remains under study.

what do the trials show?

the SURPASS program across five trials established tirzepatide's superiority over placebo and all comparators tested (including semaglutide 1 mg, insulin degludec, and insulin glargine) for both HbA1c reduction and weight loss in type 2 diabetes. the SURMOUNT program established the same pattern in obesity. SURMOUNT-5 added the first head-to-head superiority data over semaglutide 2.4 mg for weight loss.

SURPASS-1 (Lancet 2021, n=478) reported HbA1c reductions of 1.87% to 2.07% across doses versus +0.04% for placebo at 40 weeks, with 87-88% achieving HbA1c below 7% and up to 52% reaching non-diabetic HbA1c below 5.7% [4]. SURPASS-2 (NEJM 2021, n=1,879) compared tirzepatide to semaglutide 1 mg, with all three tirzepatide doses non-inferior and superior for HbA1c, and tirzepatide 15 mg producing approximately double the weight reduction of semaglutide 1 mg [5].

SURMOUNT-1 (NEJM 2022, n=2,539) in adults with obesity but without diabetes reported mean weight loss of 15.0%, 19.5%, and 20.9% at 5, 10, and 15 mg respectively versus 3.1% for placebo at 72 weeks, the largest weight-loss signal seen for any single approved medicine at that time [6]. SURMOUNT-4 (JAMA 2024) confirmed that stopping tirzepatide after reaching a weight-loss plateau leads to substantial regain (~14% over 52 weeks), demonstrating that the drug requires ongoing treatment for weight maintenance. SURMOUNT-5 (NEJM May 2025, n=751), the first head-to-head obesity trial at maximum approved doses, reported 20.2% mean weight loss for tirzepatide versus 13.7% for semaglutide 2.4 mg, with tirzepatide also showing lower GI-related discontinuation [7].

SURMOUNT-OSA (NEJM June 2024) demonstrated approximately 25-29 event-per-hour reductions in apnea-hypopnea index versus 5 for placebo at 52 weeks, with 42-50% of patients achieving remission or mild OSA, which led to the December 2024 FDA approval -- the first medication ever approved for obstructive sleep apnea [8]. the SURPASS-CVOT outcomes trial (NEJM 2025) showed tirzepatide was noninferior to dulaglutide for 3-point MACE in adults with type 2 diabetes and established cardiovascular disease, but did not demonstrate superiority over this already-effective active comparator [9].

safety profile and regulatory considerations

gastrointestinal events dominate the tolerability profile, especially during dose initiation and escalation. the label carries a boxed warning for thyroid C-cell tumors from rodent data (human relevance not established), and tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2. compounded tirzepatide is no longer legally available through most US pharmacies following the FDA's March 2025 enforcement action resolving the shortage period.

the most common adverse events in SURMOUNT trials were nausea (12-26%), diarrhea (12-17%), vomiting (5-12%), and constipation (6-11%). these are dose-related, peak during the first 4-8 weeks or after dose increases, and diminish as treatment continues. rates at maximum doses were comparable to or slightly lower than semaglutide in SURMOUNT-5. serious but less common risks include pancreatitis (uncommon but serious), gallbladder disease (rate increases with weight loss magnitude), dehydration-related acute kidney injury, and worsening diabetic retinopathy in T2D patients with rapid glycemic improvement [10].

where tirzepatide fits in the incretin landscape

tirzepatide currently leads the incretin class on weight loss and glycemic efficacy, with SURMOUNT-5 head-to-head data against semaglutide 2.4 mg. semaglutide leads on breadth of approved indications (CKD, MASH, non-diabetes cardiovascular risk) and on having an oral formulation. the next evolutionary step is retatrutide, a triple GIP/GLP-1/glucagon agonist in phase 3 that adds glucagon receptor activation for enhanced energy expenditure.

for patients with established cardiovascular disease in type 2 diabetes, semaglutide still has the placebo-controlled SUSTAIN 6 and the broader SELECT and FLOW datasets, while tirzepatide's SURPASS-CVOT was active-controlled against dulaglutide. retatrutide phase 2 data showed approximately 24% mean weight loss at 48 weeks, suggesting it may push the efficacy ceiling further if its phase 3 program succeeds. for context on how these incretin agents connect to the GH axis that includes tesamorelin and ipamorelin, the underlying biology is covered in our free peptides and your body module.